Overview

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Cyclosporine
Cyclosporins